We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Increased Assay Panel of SNPs

By Biotechdaily staff writers
Posted on 09 May 2005
An assay panel with 20,000 non-synonymous single nucleotide polymorphisms (SNPs) is now available for use in human genotyping studies.

The assay panel, from ParAllele Genotyping Services (So. More...
San Francisco, CA, USA), formerly had only 10,000 SNPs. This enlarged coding SNP panel represents genes with SNPs that code for amino acid changes, which are those believed to have the biggest impact on phenotype. The panel was developed by using the company's molecular inversion probes, which result in extremely high levels of multiplexing, essential for genotyping demands. This latest panel also includes some of those selected by ParAllele from > 25,000 previously unvalidated SNPS. The final SNP panel selection for the enlarged panel was achieved by genotyping around 300 individuals from three ethnic populations accounting for > 8 million genotypes.

"This panel enlarged to 20,000 fully validated non-synonymous SNPs not only represents a cost-effective way of achieving whole genome analysis but has the potential of an extremely high payoff, since the SNPs that we have selected for this assay panel represent those most likely to be associated with a functional response,” said Malek Farhem, M.D., Ph.D., co-founder and director of research at ParAllele.

The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome.




Related Links:
ParAllele

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.